William Blair Issues Negative Estimate for VKTX Earnings

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Stock analysts at William Blair decreased their Q2 2025 earnings per share (EPS) estimates for shares of Viking Therapeutics in a note issued to investors on Wednesday, April 23rd. William Blair analyst A. Hsieh now forecasts that the biotechnology company will earn ($0.45) per share for the quarter, down from their previous forecast of ($0.36). The consensus estimate for Viking Therapeutics’ current full-year earnings is ($1.56) per share. William Blair also issued estimates for Viking Therapeutics’ Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($1.87) EPS, Q1 2026 earnings at ($0.54) EPS, Q2 2026 earnings at ($0.55) EPS, Q3 2026 earnings at ($0.56) EPS, Q4 2026 earnings at ($0.57) EPS, FY2026 earnings at ($2.22) EPS and FY2027 earnings at ($2.79) EPS.

Other equities research analysts also recently issued research reports about the company. Citigroup started coverage on Viking Therapeutics in a report on Friday, February 7th. They issued a “neutral” rating and a $38.00 price objective on the stock. The Goldman Sachs Group started coverage on shares of Viking Therapeutics in a research note on Tuesday, April 8th. They set a “neutral” rating and a $30.00 price target on the stock. Raymond James raised their price objective on shares of Viking Therapeutics from $122.00 to $125.00 and gave the company a “strong-buy” rating in a research note on Thursday, February 6th. Maxim Group cut their target price on shares of Viking Therapeutics from $120.00 to $70.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $102.00 price target on shares of Viking Therapeutics in a research report on Thursday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $89.50.

Viking Therapeutics Stock Down 2.6 %

Shares of NASDAQ VKTX opened at $24.99 on Monday. The business’s 50 day moving average is $26.47 and its two-hundred day moving average is $40.34. Viking Therapeutics has a 52-week low of $18.92 and a 52-week high of $81.86. The firm has a market cap of $2.81 billion, a price-to-earnings ratio of -24.99 and a beta of 0.84.

Viking Therapeutics (NASDAQ:VKTX) last announced its earnings results on Wednesday, April 23rd. The biotechnology company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.07). During the same period in the prior year, the firm earned ($0.26) EPS.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. FMR LLC lifted its position in Viking Therapeutics by 0.6% in the fourth quarter. FMR LLC now owns 16,715,438 shares of the biotechnology company’s stock valued at $672,629,000 after acquiring an additional 96,008 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Viking Therapeutics by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 1,880,713 shares of the biotechnology company’s stock valued at $75,704,000 after purchasing an additional 17,046 shares during the period. Braidwell LP boosted its position in shares of Viking Therapeutics by 27.9% in the 4th quarter. Braidwell LP now owns 1,479,666 shares of the biotechnology company’s stock valued at $59,542,000 after purchasing an additional 322,689 shares during the period. Ameriprise Financial Inc. grew its stake in Viking Therapeutics by 228.5% during the 4th quarter. Ameriprise Financial Inc. now owns 1,479,596 shares of the biotechnology company’s stock worth $59,540,000 after buying an additional 1,029,125 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA increased its position in Viking Therapeutics by 446.7% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,357,241 shares of the biotechnology company’s stock worth $54,615,000 after buying an additional 1,108,972 shares during the period. Institutional investors and hedge funds own 76.03% of the company’s stock.

Insiders Place Their Bets

In related news, Director Sarah Kathryn Rouan acquired 1,240 shares of the business’s stock in a transaction on Monday, March 31st. The shares were bought at an average price of $24.15 per share, with a total value of $29,946.00. Following the completion of the acquisition, the director now owns 1,240 shares in the company, valued at $29,946. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.10% of the stock is owned by company insiders.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.